2026年7月21日，歌礼制药有限公司（股票代码：01672，股票名称：歌礼制药-B）公布翌日披露报表，披露在香港联交所场内回购200,000股普通股股份，最高回购价为每股8.65港元，最低回购价为每股8.01港元，合计支付约169.02万港元（即1,690,160港元），占本次事件前已发行股本的0.0188%。
根据公告，当日公司还注销了此前于2025年4月至2026年6月期间先后回购的9,386,000股股份以及1,300,000股库存股，共计减少已发行股份10,686,000股。上述被注销股份分别占该事项发生前现有已发行股本约0.8843%。同日注销完成后，公司已发行股份数为1,051,984,845股，库存股份余数为5,784,210股，总股份数1,057,769,055股。
公司此前于2026年6月29日通过股份购回授权，可回购股份总数为106,137,084股，截至公告日已于香港联交所或其他证券交易所累积回购1,345,000股，约占授权通过当日已发行股本的0.1267%。公司声明所有回购及注销程序均符合香港联交所证券上市规则及相关法规。公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.